Chimeric molecules providing targeted costimulation for adoptive cell therapy
US11697677B2 · kind B2 · utility
1Cited by
33References
25Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 25, 2022 |
| Grant date | Jul 11, 2023 |
| Priority date | — |
| Expiry date | Aug 25, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/33
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a chimeric molecule useful in adoptive cell therapy (ACT), and cells comprising the same. The chimeric molecule can act as a modulator of cellular activity enhancing responses when an endogenous T-cell receptor (TCR) is engaged with its cognate antigen. The present invention also provides proteins, nucleic acids encoding the chimeric molecule and therapeutic uses thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.